COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
None listed
Sponsors
Yokohama City University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: <A prospective observational study> Patients who meet all of the following criteria are eligible (1) Those who are 20 years of age or older at the time of registration. (2) Positive results of gene amplification test (PCR or Lamp test) or antigen test for SARS-CoV-2 in pharyngeal swabs, nasopharyngeal swabs, or saliva. (3) A person with any symptoms caused by SARS-CoV-2 infection (4) Those who need to be hospitalized for SARS-CoV-2 infection (5) Patients who have given their written informed consent to participate in this study. <A retrospective observational study> Patients who meet all of the following criteria are eligible (1) Those who are 20 years of age or older at the time of registration. (2) Positive results of gene amplification test (PCR or Lamp test) or antigen test for SARS-CoV-2 in pharyngeal swabs, nasopharyngeal swabs, or saliva. (3) A person with any symptoms caused by COVID-19 (4) Those who had needed to be hospitalized for COVID-19 (5) The patient who has had at least one blood draw within 30 days of the onset from the disease and the residual serum must have been stored at least 200 micro litter (6) Patients who meet any of the following 1. Patients who are outpatients or continuously hospitalized at the time of registration and who have given their written informed consent for this study 2. Patients who have already completed their hospital visits and have not applied for opt-out denial of the information use
Exclusion criteria
Exclusion criteria: <A prospective observational study> Patients who meet the following criteria are excluded (1) Patients with mental illness or other conditions that are believed to affect their ability to consent. (2) Other patients who are deemed by the researcher to be unsuitable to participate in the research. <A retrospective observational study> There are no exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation between neutralizing activity and NP antibody titer during the acute phase of SARS-CoV-2 infection | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) The correlation between neutralizing activity and SP antibody titer in the acute phase of SARS-CoV-2 infection (2) The correlation between the NP or the SP antibody titers and the neutralizing activity by the time from the onset of symptoms (10 days or less, 11 to 20 days, 21 to 30 days) (3) The positive rate of the NP antibody test (4) The effect of administered drugs on the neutralizing activity (5) The relationship between neutralizing activity and the clinical outcomes | — |
Countries
Japan
Contacts
Public ContactTakahiro Mihara
Yokohama City University School of Medicine Graduate School of Data Science
Outcome results
None listed